Identification of new prognostic molecular markers in glioblastoma: a single-center retrospective study
We identified new prognostic markers in GBM, showing for the first time that EGFR substitutions improve OS. Validation in external cohorts and preclinical studies is needed.
Authors
- Delphine Larrieu (ORCID: https://orcid.org/0000-0002-2335-9361)
- F.E. Roux
- Amélie Lusque (ORCID: https://orcid.org/0000-0001-9691-5536)
- Solène Evrard (ORCID: https://orcid.org/0000-0001-9669-8316)
- Ilfad Blazevic (ORCID: https://orcid.org/0000-0001-8124-8929)
- Damien Pouessel (ORCID: https://orcid.org/0000-0003-4030-8299)
- Adèle Meola
- Aurore Siegfried (ORCID: https://orcid.org/0000-0001-9152-4616)
- Delphine Dghayem (ORCID: https://orcid.org/0000-0003-4849-5295)
- Bertille Segier (ORCID: https://orcid.org/0009-0005-3492-3780)
- M GUILLAUMEY
- Sandra Soares
- Elizabeth Cohen-Jonathan Moyal
Institutions
- Inserm (FR)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Centre de Recherches en Cancérologie de Toulouse (FR)
- Institut universitaire du cancer de Toulouse Oncopole (FR)
- Toulouse Mathematics Institute (FR)
- Institut Claudius Regaud (FR)
- Hôpital Purpan (FR)
- Hôpital Paule de Viguier (FR)
Publication Details
- Journal
- The Oncologist
- Published
- 2026-03-13
- DOI
- https://doi.org/10.1093/oncolo/oyag095
- Primary Topic
- Glioma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00